News and Trends 15 Dec 2022 EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation …candidate for the treatment of Canavan disease (CD). EMA OD designation’s aim is to encourage the development of treatments for life-threatening rare conditions by providing incentives such as protocol assistance,… December 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2018 Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates …active. The two previous studies looked at the candidate as a monotherapy, which doesn’t appear to have gone too well. The remaining trial is testing MEDI0680 in combination with another… February 6, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Nov 2024 Cystic fibrosis: Five biotechs breathing life into the therapeutic space …of the drug helped clear mucus in the airway in sheep models. The drug candidate is currently in phase 2 studies, and the first person was dosed back in July…. November 7, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2016 After only 6 months, Akarna seals the deal with Allergan for €44.8M upfront …old company was offered a €44.8M upfront payment by Allergan. Now, the Irish giant owns all rights to Akarna’s lead candidate, AKN-083, in addition to several other candidates. AKN-083 is… September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 25 Mar 2019 Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug …were scheduled to start a phase III trial of an antibody treatment for Alzheimer’s. Although the antibody is not the same as Biogen’s, both antibodies target pathological forms of a… March 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 License submitted to FDA for drug to help those with large B-cell lymphoma A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company… July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 30 Oct 2017 Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014 …So what was the technology that Covagen developed that J&J took such an interest in? We started with the development of antibody alternatives, with Fynomers — small proteins of about… October 30, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s …candidates that originate from F-star’s development pipeline. Each drug has been developed for a specific genetically validated target and uses Denali’s Antibody Transport Vehicle (ATV) to help therapeutics across the… January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2020 Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease,… April 2, 2020 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy …the power’ of the immune system. One of its candidates is an antibody that targets the CD38 immune checkpoint, which is a marker of cell activation that is expressed by… November 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2018 Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema …the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against the human placental… July 20, 2018 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2019 Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents …to CD38 for the treatment of cancer, including multiple myeloma. MOR202 induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of multiple myeloma cells. (Source: MorphoSys) With… January 28, 2019 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email